文献速递血液净化与透析

血液透析中心丙型肝炎病毒筛查频率的成本效果微模拟研究

A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers.
PubMed 文献 · J Am Soc Nephrol · 2023-01-01

本研究采用丙型肝炎病毒(HCV)筛查、治疗和疾病微模拟模型,以美国中心血液透析人群为队列,比较KDIGO 2018指南推荐的每6个月筛查与每年、每2年、仅透析起始时筛查及不筛查的成本效果。结果显示,仅透析起始时筛查的ICER为每获得1个QALY 82,739美元,每2年筛查为140,193美元,每6个月筛查为934,757美元;在支付意愿阈值为每QALY 150,000美元时,每6个月筛查从不具有成本效果。

要点

  • 仅透析起始时筛查较不筛查的ICER为每QALY 82,739美元。
  • 每2年筛查较仅透析起始时筛查的ICER为每QALY 140,193美元。
  • 每6个月筛查的ICER为每QALY 934,757美元,在150,000美元/QALY阈值下从不具有成本效果。

核心结论

  • KDIGO推荐的每6个月HCV筛查间隔似乎不是医疗资源的成本效果使用方式,提示应考虑重新评估更低频率的筛查策略。

研究设计与样本

  • 研究采用HCV筛查、治疗和疾病微模拟模型,以代表美国中心血液透析人群的队列进行模拟。

主要发现

  • 仅透析起始时筛查的HCV治愈率为79%,较不筛查的ICER为每QALY 82,739美元。
  • 每2年筛查较仅透析起始时筛查将治愈率提高至88%,肝相关死亡减少52%,ICER为每QALY 140,193美元。
  • 每6个月筛查的ICER为每QALY 934,757美元;在每QALY 150,000美元支付意愿阈值下,每6个月筛查从不具有成本效果。

关键数值与推荐

  • KDIGO 2018指南推荐每6个月进行HCV筛查。
  • 模型中每种策略均模拟1%中心发生HCV暴发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National guidelines recommend twice-yearly hepatitis C virus (HCV) screening for patients receiving in-center hemodialysis. However, studies examining the cost-effectiveness of HCV screening methods or frequencies are lacking. METHODS: We populated an HCV screening, treatment, and disease microsimulation model with a cohort representative of the US in-center hemodialysis population. Clinical outcomes, costs, and cost-effectiveness of the Kidney Disease Improving Global Outcomes (KDIGO) 2018 guidelines-endorsed HCV screening frequency (every 6 months) were compared with less frequent periodic screening (yearly, every 2 years), screening only at hemodialysis initiation, and no screening. We estimated expected quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) between each screening strategy and the next less expensive alternative strategy, from a health care sector perspective, in 2019 US dollars. For each strategy, we modeled an HCV outbreak occurring in 1% of centers. In sensitivity analyses, we varied mortality, linkage to HCV cure, screening method (ribonucleic acid versus antibody testing), test sensitivity, HCV infection rates, and outbreak frequencies. RESULTS: Screening only at hemodialysis initiation yielded HCV cure rates of 79%, with an ICER of $82,739 per QALY saved compared with no testing. Compared with screening at hemodialysis entry only, screening every 2 years increased cure rates to 88% and decreased liver-related deaths by 52%, with an ICER of $140,193. Screening every 6 months had an ICER of $934,757; in sensitivity analyses using a willingness-to-pay threshold of $150,000 per QALY gained, screening every 6 months was never cost-effective. CONCLUSIONS: The KDIGO-recommended HCV screening interval (every 6 months) does not seem to be a cost-effective use of health care resources, suggesting that re-evaluation of less-frequent screening strategies should be considered.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Epstein RL, Pramanick T, Baptiste D, et al. A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers. J Am Soc Nephrol. 2023. PMID: 36735375. doi:10.1681/ASN.2022030245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。